Precision Endpoints for Contemporary Precision Oncology Trials.
Cancer Discov
; 14(4): 573-578, 2024 Apr 04.
Article
em En
| MEDLINE
| ID: mdl-38571432
ABSTRACT
SUMMARY:
Traditional endpoints such as progression-free survival and overall survival do not fully capture the pharmacologic and pharmacodynamic effects of a therapeutic intervention. Incorporating mechanism-driven biomarkers and validated surrogate proximal endpoints can provide orthogonal readouts of anti-tumor activity and delineate the relative contribution of treatment components on an individual level, highlighting the limitation of solely relying on aggregated readouts from clinical trials to facilitate go/no-go decisions for precision therapies.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Neoplasias
Limite:
Humans
Idioma:
En
Revista:
Cancer Discov
Ano de publicação:
2024
Tipo de documento:
Article
País de afiliação:
Singapura